Killing effect of Ad5/F35-APE1 siRNA recombinant adenovirus in combination with hematoporphrphyrin derivative-mediated photodynamic therapy on human nonsmall cell lung cancer

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Xia, Lei ^a   Guan, Wei ^a   Wang, Dong ^a   Zhang, Yun Song ^a   Zeng, Lin Li ^a   Li, Zeng Peng ^a   Wang, Ge ^a   Yang, Zhen Zhou ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; DNA (APURINIC OR APYRIMIDINIC SITE) LYASE; ERYTHROCYTE PROTOPORPHYRIN; HEMATOPROTOPORPHYRIN DERIVATIVE; REACTIVE OXYGEN METABOLITE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; APEX1 PROTEIN, HUMAN; HEMATOPORPHYRIN;

ADENOVIRUS 5; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; PHOTODYNAMIC THERAPY; VIRUS RECOMBINANT; WESTERN BLOTTING; ADENOVIRUS; APOPTOSIS; GENE THERAPY; GENE VECTOR; GENETICS; INFLAMMATION; LUNG TUMOR; METABOLISM; METHODOLOGY; PATHOLOGY; PHOTOCHEMOTHERAPY; TUMOR CELL LINE;

ADENOVIRIDAE; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DNA-(APURINIC OR APYRIMIDINIC SITE) LYASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENETIC THERAPY; GENETIC VECTORS; HEMATOPORPHYRINS; HUMANS; INFLAMMATION; LUNG NEOPLASMS; PHOTOCHEMOTHERAPY; REACTIVE OXYGEN SPECIES; RNA, SMALL INTERFERING;

EID: 84874634568     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/957913     Document Type: Article

References (22)

1. Jemal A., Clegg L. X., Ward E., Ries L. A. G., Wu X., Jamison P. M., Wingo P. A., Howe H. L., Anderson R. N., Edwards B. K., Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer 2004 101 1 3 27 2-s2.0-3042628862 10.1002/cncr.20288 (Pubitemid 38812419)
2. Kamangar F., Dores G. M., Anderson W. F., Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. Journal of Clinical Oncology 2006 24 14 2137 2150 2-s2.0-33646568784 10.1200/JCO.2005.05. 2308 (Pubitemid 46655601)
3. Ding X., Xu Q., Liu F., Zhou P., Gu Y., Zeng J., An J., Dai W., Li X., Hematoporphyrin monomethyl ether photodynamic damage on HeLa cells by means of reactive oxygen species production and cytosolic free calcium concentration elevation. Cancer Letters 2004 216 1 43 54 2-s2.0-6944249320 10.1016/j.canlet.2004.07.005 (Pubitemid 39410495)
4. Kato H., Usuda J., Okunaka T., Furukawa K., Honda H., Sakaniwa N., Suga Y., Hirata T., Ohtani K., Inoue T., Maehara S., Kubota M., Yamada K., Tsuitsui H., Basic and clinical research on photodynamic therapy at Tokyo Medical University Hospital. Lasers in Surgery and Medicine 2006 38 5 371 375 2-s2.0-33745714010 10.1002/lsm.20346
5. Agostinis P., Berg K., Cengel K. A., Photodynamic therapy of cancer: an update. CA: A Cancer Journal for Clinicians 2011 61 4 250 281
6. Dabrowski J. M., Arnaut L. G., Pereira M. M., Combined effects between singlet oxygen and hydroxyl radical in photodynamic therapy with photostable bacteriochlorins:evidence from intracellular fluorescence and increased photodynamic efficacy in vitro. Free Radical Biology & Medicine 2012 52 7 1188 1200
7. Puglisi F., Aprile G., Minisini A. M., Barbone F., Cataldi P., Tell G., Kelley M. R., Damante G., Beltrami C. A., Di Loreto C., Prognostic significance of Ape1/ref-1 subcellular localization in non-small cell lung carcinomas. Anticancer Research 2001 21 6 4041 4049 2-s2.0-0035570805 (Pubitemid 34229282)
8. Evans A. R., Limp-Foster M., Kelley M. R., Going APE over ref-1. Mutation Research 2000 461 2 83 108 2-s2.0-0034676227 10.1016/S0921-8777(00)00046-X
9. Kim Y. W., Bae S. M., Battogtokh G., Synergistic anti-tumor effects of combination of photodynamic therapy and arsenic compound in cervical cancer cells: in vivo and in vitro studies. PLoS One 2012 7 6, article e38583
10. Manoto S. L., Sekhejane P. R., Houreld N. N., Localization and phototoxic effect of zinc sulfophthalocyanine photosensitizer in human colon (DLD-1) and lung (A549) carcinoma cells (in vitro). Photodiagnosis and Photodynamic Therapy 2011 9 1 52 59
11. Jedrych E., Chudy M., Dybko A., The microfluidic system for studies of carcinoma and normal cells interactions after photodynamic therapy (PDT) procedures. Biomicrofluidics 2011 5 4 41101 411016
12. Ziel K. A., Campbell C. C., Wilson G. L., Gillespie M. N., Ref-1/Ape is critical for formation of the hypoxia-inducible transcriptional complex on the hypoxic response element of the rat pulmonary artery endothelial cell VEGF gene. FASEB Journal 2004 18 9 986 988 2-s2.0-6944236323 10.1096/fj.03-1160fje (Pubitemid 39561500)
13. Nguyen T., Menocal E. M., Harborth J., Fruehauf J. H., RNAi therapeutics: an update on delivery. Current Opinion in Molecular Therapeutics 2008 10 2 158 167 2-s2.0-41849149676 (Pubitemid 351498878)
14. Paddison P. J., Caudy A. A., Hannon G. J., Stable suppression of gene expression by RNAi in mammalian cells. Proceedings of the National Academy of Sciences of the United States of America 2002 99 3 1443 1448 2-s2.0-0037022382 10.1073/pnas.032652399 (Pubitemid 34136512)
15. Brummelkamp T. R., Bernards R., Agami R., A system for stable expression of short interfering RNAs in mammalian cells. Science 2002 296 5567 550 553 2-s2.0-0037134020 10.1126/science.1068999 (Pubitemid 34408678)
16. Paul C. P., Good P. D., Winer I., Engelke D. R., Effective expression of small interfering RNA in human cells. Nature Biotechnology 2002 20 5 505 508 2-s2.0-0036251639 10.1038/nbt0502-505 (Pubitemid 34495939)
17. Shuey D. J., McCallus D. E., Giordano T., RNAi: gene-silencing in therapeutic intervention. Drug Discovery Today 2002 7 20 1040 1046 2-s2.0-0037107886 10.1016/S1359-6446(02)02474-1
18. Wang D., Luo M., Kelley M. R., Human apurinic endonuclease 1 (APE1) expression and prognostic significance in osteosarcoma: enhanced sensitivity of osteosarcoma to DNA damaging agents using silencing RNA APE1 expression inhibition. Molecular Cancer Therapeutics 2004 3 6 679 686 2-s2.0-4444327784 (Pubitemid 39193748)
19. Walker L. J., Craig R. B., Harris A. L., Hickson I. D., A role for the human DNA repair enzyme HAP1 in cellular protection against DNA damaging agents and hypoxic stress. Nucleic Acids Research 1994 22 23 4884 4889 2-s2.0-0028596574
20. Ono Y., Furuta T., Ohmoto T., Akiyama K., Seki S., Stable expression in rat glioma cells of sense and antisense nucleic acids to a human multifunctional DNA repair enzyme, APEX nuclease. Mutation Research 1994 315 1 55 63 2-s2.0-0028244814 10.1016/0921-8777(94)90028-0 (Pubitemid 24208288)
21. McNeill D. R., Wilson D. M. III, A dominant-negative form of the major human abasic endonuclease enhances cellular sensitivity to laboratory and clinical DNA-damaging agents. Molecular Cancer Research 2007 5 1 61 70 2-s2.0-33846976720 10.1158/1541-7786.MCR-06-0329
22. Yang Z. Z., Chen X. H., Wang D., Experimental study enhancing the chemosensitivity of multiple myeloma to melphalan by using a tissue-specific APE1-silencing RNA expression vector. Clinical Lymphoma and Myeloma 2007 7 4 296 304 2-s2.0-33947129762 10.3816/CLM.2007.n.006 (Pubitemid 46408195)